Titlebook: Recombinant Protein Drugs; Peter Buckel Book 2001 Birkh?user Verlag 2001 clinic.clinical trial.development.drug.drug discovery.drugs.futur

網(wǎng)絡(luò)添麻煩

obeisance

Recombinant interferon - the 20th anniversarymouse IFN and of the control of its expression, it became evident that cloning of the chromosomal IFN gene would lead to a wealth of information unattainable by any other means. Moreover, the undertaking was a challenge, since pure IFN was extremely hard to come by, its structure was unknown and wou

Obedient

promote

Harpoon

吞下

commute

Fatten

Improving protein therapeutics: the evolution of the modern pharmacopoeia number in the hundreds [1, 2] and include monoclonal antibodies, growth factors, cytokines, soluble receptors, hormones and proteins to block the function of a variety of infectious agents. Proteins are specific, exert their effects at low concentrations, and their virtually limitless number enable

確保

Principles of gene transfer and foreign protein expression for human gene therapyl development of efficient and targeted vectors to deliver therapeutic foreign genetic elements into defective cells for the purpose of complementing underlying genetic defects responsible for human genetic disease. The initial models for this approach were the single-gene Mendelian defects associat

冒號

Book 2001em belonging to the most successful pharmaceutical products. More than thirty different proteins are available for a variety of clinical applications, over 300 proteins are presently being evaluated in clinical trials. In this new volume of the MDT series, historical, technical and clinical aspects